• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Sangamo Therapeutics Inc.

    5/12/25 5:32:23 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SGMO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 8)


    SANGAMO THERAPEUTICS, INC

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    800677106

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    800677106


    1Names of Reporting Persons

    WASATCH ADVISORS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    10,847,230.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    11,630,671.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    11,630,671.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.2 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    SANGAMO THERAPEUTICS, INC
    (b)Address of issuer's principal executive offices:

    501 CANAL BLVD., 501 CANAL BLVD., RICHMOND, CALIFORNIA, 94084
    Item 2. 
    (a)Name of person filing:

    Wasatch Advisors LP
    (b)Address or principal business office or, if none, residence:

    505 Wakara Way, 3rd Floor, Salt Lake City, 84108, United States
    (c)Citizenship:

    DELAWARE
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    800677106
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    11,630,671
    (b)Percent of class:

    5.2  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    10,847,230

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    11,630,671

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    WASATCH ADVISORS LP
     
    Signature:Mike Yeates
    Name/Title:CEO
    Date:05/12/2025
    Get the next $SGMO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SGMO

    DatePrice TargetRatingAnalyst
    12/13/2024$7.00Hold → Buy
    Truist
    12/10/2024$10.00Buy
    H.C. Wainwright
    11/3/2023$6.00 → $2.00Outperform → Sector Perform
    RBC Capital Mkts
    4/28/2023$5.00 → $1.50Neutral → Underperform
    BofA Securities
    2/27/2023$16.00Neutral → Outperform
    Wedbush
    1/6/2023$8.00 → $5.00Buy → Neutral
    BofA Securities
    6/13/2022$5.00Neutral
    Wedbush
    More analyst ratings

    $SGMO
    SEC Filings

    View All

    SEC Form S-8 filed by Sangamo Therapeutics Inc.

    S-8 - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

    8/8/25 4:27:13 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-Q filed by Sangamo Therapeutics Inc.

    10-Q - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

    8/7/25 4:05:16 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SANGAMO THERAPEUTICS, INC (0001001233) (Filer)

    8/7/25 4:02:57 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

    Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval. First clinical site initiated for Phase 1/2 STAND study in chronic neuropathic pain. Expect to dose first patient in fall of 2025, with preliminary proof of efficacy data anticipated in late 2026. Held productive meeting with Medicines and Healthcare products Regulatory Agency (MHRA) to discuss prion disease study ahead of anticipated Clinical Trial Application (CTA) submissi

    8/7/25 4:01:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

    RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, August 7, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be

    7/31/25 4:05:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease

    STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval Isaralgagene civaparvovec showed a favorable safety and tolerability profile Sangamo intends to submit a Biologics License Application (BLA) in 2026 Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced positive topline results from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for the treatment of adults with Fabry diseas

    6/24/25 8:05:00 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, CHIEF FINANCIAL OFFICER Duraibabu Prathyusha covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 746,279 units (SEC Form 4)

    4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

    7/24/25 4:59:23 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PRESIDENT, CEO AND DIRECTOR Macrae Sandy covered exercise/tax liability with 126,950 shares, decreasing direct ownership by 5% to 2,191,460 units (SEC Form 4)

    4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

    7/24/25 4:58:36 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP, CHIEF LEGAL OFFICER, SECY Willoughby Scott B. covered exercise/tax liability with 31,866 shares, decreasing direct ownership by 4% to 749,677 units (SEC Form 4)

    4 - SANGAMO THERAPEUTICS, INC (0001001233) (Issuer)

    7/24/25 4:57:27 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sangamo Therapeutics upgraded by Truist with a new price target

    Truist upgraded Sangamo Therapeutics from Hold to Buy and set a new price target of $7.00

    12/13/24 8:18:20 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright reiterated coverage on Sangamo Therapeutics with a new price target

    H.C. Wainwright reiterated coverage of Sangamo Therapeutics with a rating of Buy and set a new price target of $10.00

    12/10/24 11:58:57 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Sangamo Therapeutics from Outperform to Sector Perform and set a new price target of $2.00 from $6.00 previously

    11/3/23 7:45:03 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Financials

    Live finance-specific insights

    View All

    Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2025 Financial Results

    Announced positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) has agreed will serve as primary basis of approval. First clinical site initiated for Phase 1/2 STAND study in chronic neuropathic pain. Expect to dose first patient in fall of 2025, with preliminary proof of efficacy data anticipated in late 2026. Held productive meeting with Medicines and Healthcare products Regulatory Agency (MHRA) to discuss prion disease study ahead of anticipated Clinical Trial Application (CTA) submissi

    8/7/25 4:01:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Announces Second Quarter 2025 Earnings Call

    RICHMOND, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company today announced that the company has scheduled the release of its second quarter 2025 financial results after the markets close on Thursday, August 7, 2025. The company will hold a conference call at 4:30 p.m. Eastern on Thursday, August 7, which will remain open to the public. During the conference call, the company will review its financial results and provide business updates. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be

    7/31/25 4:05:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Sangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same Day

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced that the first quarter earnings call originally scheduled for 4:30p.m. Eastern on Monday, May 12 will be postponed to 6:30p.m. Eastern on Monday, May 12, 2025. The registration and access link previously provided remains the same. Participants should register for, and access, the call using this link. While not required, it is recommended to join 10 minutes prior to the event start. Once registered, participants will be given the option to either dial into the call with the number and unique passcode provided, or to use the dial-out option to connect their phone instantly. The link to access the live web

    5/12/25 4:00:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

    SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

    11/12/24 4:53:35 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

    SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

    11/4/24 1:54:32 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sangamo Therapeutics Inc.

    SC 13G/A - SANGAMO THERAPEUTICS, INC (0001001233) (Subject)

    8/16/24 6:40:25 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $SGMO
    Leadership Updates

    Live Leadership Updates

    View All

    Sangamo Therapeutics Announces Appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, today announced the appointment of Lisa Rojkjaer, M.D., as Chief Medical Officer. She will serve on the Executive Leadership team and report to Nathalie Dubois-Stringfellow, Sangamo's Chief Development Officer. Dr Rojkjaer succeeds Bettina Cockroft, M.D., M.B.A, who is leaving the company to pursue other opportunities. We thank her for her contributions. "We are thrilled to welcome Dr. Rojkjaer, an experienced physician, drug developer, and regulatory expert, to the Sangamo team," said Nathalie Dubois-Stringfellow, Chief Development Officer at Sangamo. "Her deep industry experience across all stages of clinical developm

    5/16/23 8:00:00 AM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Organogenesis Appoints Prathyusha Duraibabu to Board of Directors

    CANTON, Mass., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (NASDAQ:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Prathyusha Duraibabu to the Company's Board of Directors, effective November 19, 2021. Ms. Duraibabu will serve as an independent director of the Company and member of the Audit Committee of the Board. "Prathyusha is a proven leader who brings significant expertise from a more than 24-year career in the technology and healthcare sectors, and has held senior leadership positio

    11/22/21 7:00:00 AM ET
    $ORGO
    $PACB
    $SGMO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Sangamo Therapeutics Appoints Prathyusha Duraibabu, CPA, MBA, to Chief Financial Officer

    Sangamo Therapeutics, Inc. (NASDAQ:SGMO), a genomic medicine company, announced today the appointment of Prathyusha Duraibabu, CPA, MBA as Senior Vice President and Chief Financial Officer, effective June 1, 2021. Ms. Duraibabu will lead all financial activities and report to the Chief Executive Officer. "Prathyusha has served as our Principal Accounting Officer for nearly two years and has contributed significantly to Sangamo with her wealth of experience and proven track record in optimizing financial strategy and operations, driving organizational change, and building diverse teams," said Sandy Macrae, Chief Executive Officer of Sangamo. "I look forward to Prathyusha's leadership and sa

    5/24/21 4:15:00 PM ET
    $SGMO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care